- Home
- RA vs MYGN Comparison
RA vs MYGN Comparison
Compare RA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RA
- MYGN
- Stock Information
- Founded
- RA 2016
- MYGN 1991
- Country
- RA United States
- MYGN United States
- Employees
- RA 1260
- MYGN N/A
- Industry
- RA Investment Managers
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RA Finance
- MYGN Health Care
- Exchange
- RA Nasdaq
- MYGN Nasdaq
- Market Cap
- RA 711.7M
- MYGN 744.7M
- IPO Year
- RA N/A
- MYGN 1995
- Fundamental
- Price
- RA $13.50
- MYGN $5.60
- Analyst Decision
- RA
- MYGN Hold
- Analyst Count
- RA 0
- MYGN 15
- Target Price
- RA N/A
- MYGN $15.14
- AVG Volume (30 Days)
- RA 280.8K
- MYGN 1.6M
- Earning Date
- RA 01-01-0001
- MYGN 08-05-2025
- Dividend Yield
- RA 14.73%
- MYGN N/A
- EPS Growth
- RA N/A
- MYGN N/A
- EPS
- RA N/A
- MYGN N/A
- Revenue
- RA N/A
- MYGN $831,300,000.00
- Revenue This Year
- RA N/A
- MYGN N/A
- Revenue Next Year
- RA N/A
- MYGN $6.68
- P/E Ratio
- RA N/A
- MYGN N/A
- Revenue Growth
- RA N/A
- MYGN 7.38
- 52 Week Low
- RA $11.89
- MYGN $3.81
- 52 Week High
- RA $17.32
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- RA 79.13
- MYGN 59.81
- Support Level
- RA $12.81
- MYGN $4.90
- Resistance Level
- RA $12.94
- MYGN $5.74
- Average True Range (ATR)
- RA 0.09
- MYGN 0.27
- MACD
- RA 0.06
- MYGN 0.10
- Stochastic Oscillator
- RA 97.18
- MYGN 85.71
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.